PhRMA launches biologics and biosimilars online resources

Andrew Powaleny   |     December 17, 2015   |   SHARE THIS


Biological medicines often represent the cutting-edge of biomedical research and have revolutionized the treatment of a variety of medical illnesses and conditions that presently have no other treatments available. A biosimilar product is exactly what its name implies — it is a biologic that is “similar” to another biologic drug already approved by the FDA. To help increase awareness and understanding of the important scientific, regulatory and reimbursement policies for these medicines, PhRMA is excited to launch a new section of our website today that provides educational resources on these topics.

Within the new website section, you can find the following information:

  • How biologics and biosimilars work;
  • What data protection measures are in place to promote research and development of these medicines; and,
  • How science-based regulatory policies protect patient safety and facilitate health care provider and patient choice.

Additionally, a number of downloadable fact sheets and infographics are available on more in-depth biologics and biosimilars topics. As the regulatory environment surrounding these medicines continues to evolve, PhRMA will develop and offer additional resources on the page that provide key facts on these milestones.Biologics_icon.jpg

Our goal is to create a comprehensive source of information on biologics and biosimilars, so that we can help improve awareness, science and evidence-based decision-making and patient choice.  

To access the new biologics and biosimilars web page, go to:  www.PhRMA.org/Biosimilars



Andrew Powaleny

Andrew Powaleny is Senior Director of Public Affairs at PhRMA and leads the organizations scientific communications. Before joining PhRMA in 2015, he worked in public affairs for a small firm in Washington, DC and served as Deputy Press Secretary for the House Committee on Energy and Commerce. Andrew came to Washington, D.C. via Connecticut with a degree from Eastern Connecticut State University where he majored in public policy and government. Andrew is active as a runner and volunteer with the DC Front Runners; most recently serving on its Board of Directors for three years as co-race director. He is also a member of the NLGJA: The Association of LGBTQ Journalists and mentors students through his alumni association with The Fund for American Studies. Andrew is passionate about scientific innovation, especially for mental illness, and his heroes are the men and women of America’s biopharmaceutical research companies.

Topics: Biologics and Biosimilars

Search the Catalyst

View Posts by Topic

see all

View Posts by Date

see all

Subscribe to Email Updates